Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Altimmune Inc (ALT)

Altimmune Inc (ALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 276,583
  • Shares Outstanding, K 39,739
  • Annual Sales, $ 8,190 K
  • Annual Income, $ -49,040 K
  • 60-Month Beta 1.43
  • Price/Sales 80.25
  • Price/Cash Flow N/A
  • Price/Book 1.36
Trade ALT with:

Options Overview Details

View History
  • Implied Volatility 76.40% ( +1.37%)
  • Historical Volatility 50.20%
  • IV Percentile 11%
  • IV Rank 10.20%
  • IV High 179.69% on 05/05/21
  • IV Low 64.66% on 10/20/21
  • Put/Call Vol Ratio 0.52
  • Today's Volume 94
  • Volume Avg (30-Day) 350
  • Put/Call OI Ratio 1.60
  • Today's Open Interest 1,141
  • Open Int (30-Day) 4,320

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.64
  • Number of Estimates 4
  • High Estimate -0.44
  • Low Estimate -0.89
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -276.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.88 +3.78%
on 01/20/22
9.67 -26.16%
on 01/03/22
-2.08 (-22.56%)
since 12/21/21
3-Month
6.88 +3.78%
on 01/20/22
11.75 -39.23%
on 10/26/21
-4.66 (-39.49%)
since 10/21/21
52-Week
6.88 +3.78%
on 01/20/22
24.61 -70.99%
on 02/18/21
-5.77 (-44.69%)
since 01/21/21

Most Recent Stories

More News
Altimmune Enters Oversold Territory (ALT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ALT : 7.18 (+3.16%)
Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr....

ALT : 7.18 (+3.16%)
Altimmune Appoints Richard Eisenstadt as Chief Financial Officer

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company focused on developing...

ALT : 7.18 (+3.16%)
Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the...

ALT : 7.18 (+3.16%)
Altimmune to Present at Upcoming Investor and Scientific Conferences

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that...

ALT : 7.18 (+3.16%)
Altimmune, Inc. (ALT) Reports Q3 Loss, Tops Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of -125.00% and 49.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ALT : 7.18 (+3.16%)
Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

Exploratory MRI-PDFF analysis of subjects with hepatic steatosis in recently completed Phase 1 study of pemvidutide shows reduction of liver fat to...

ALT : 7.18 (+3.16%)
Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it...

ALT : 7.18 (+3.16%)
Altimmune, Inc. (ALT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALT : 7.18 (+3.16%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors...

ALT : 7.18 (+3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 7.82
2nd Resistance Point 7.62
1st Resistance Point 7.29
Last Price 7.18
1st Support Level 6.76
2nd Support Level 6.55
3rd Support Level 6.22

See More

52-Week High 24.61
Fibonacci 61.8% 17.84
Fibonacci 50% 15.75
Fibonacci 38.2% 13.65
Last Price 7.18
52-Week Low 6.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar